Case study on the use of integrated approaches to testing and assessment for identification and characterisation of parkinsonian hazard liability of deguelin by an aop-based testing and read across approach

................................................................................................................................................. 8

[1]  E. Richfield,et al.  Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. , 2002, Neurotoxicology.

[2]  P. Eriksson,et al.  Neonatal exposure to DDT induces increased susceptibility to pyrethroid (bioallethrin) exposure at adult age.--Changes in cholinergic muscarinic receptor and behavioural variables. , 1993, Toxicology.

[3]  Hsiao-Chun Cheng,et al.  The WldS mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro‐striatal pathway in vivo , 2010, Journal of neurochemistry.

[4]  Robert J Kavlock,et al.  Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  J. Levin,et al.  Pesticide/Environmental Exposures and Parkinson's Disease in East Texas , 2008, Journal of agromedicine.

[6]  J. Pezzuto,et al.  Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats , 2001, Cancer Chemotherapy and Pharmacology.

[7]  J. Molnár,et al.  In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. , 2005, In vivo.

[8]  Sarah E. Lacher,et al.  P-Glycoprotein Transport of Neurotoxic Pesticides , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[9]  E. Evangelou,et al.  Literature review on epidemiological studies linking exposure to pesticides and health effects , 2013 .

[10]  R. Agarwal,et al.  Functional impairment of blood-brain barrier following pesticide exposure during early development in rats , 1999, Human & experimental toxicology.

[11]  Päivi Tammela,et al.  Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives. , 2017, Molecular pharmaceutics.

[12]  Sankalp Jain,et al.  Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP , 2017, Journal of Computer-Aided Molecular Design.

[13]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[14]  Alicia Paini,et al.  Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits , 2018, OECD Series on Adverse Outcome Pathways.

[15]  W. Hong,et al.  Structural basis for depletion of heat shock protein 90 client proteins by deguelin. , 2007, Journal of the National Cancer Institute.

[16]  T. Maeda,et al.  Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines , 2015, BioMed research international.

[17]  T. Sherer,et al.  Complex I and Parkinson's Disease , 2001, IUBMB life.

[18]  E. Holland,et al.  A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells. , 2014, Assay and drug development technologies.

[19]  A. Heyndrickx,et al.  A case of fatal rotenone poisoning in a child. , 1986, Journal of forensic sciences.

[20]  Pierluigi Caboni,et al.  Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. , 2004, Chemical research in toxicology.

[21]  Ryszard Laskowski,et al.  Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia† , 2017, EFSA journal. European Food Safety Authority.

[22]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[23]  Wenbin Liu,et al.  Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma , 2017, EBioMedicine.

[24]  Claudia M Testa,et al.  Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. , 2005, Brain research. Molecular brain research.

[25]  A. Matsuno-Yagi,et al.  Molecular remedy of complex I defects: rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Raymond R Tice,et al.  A High-Throughput Approach to Identify Specific Neurotoxicants / Developmental Toxicants in Human Neuronal Cell Function Assays , 2018, ALTEX.

[27]  E. Melamed,et al.  Immunity of Fetal Mice to Prenatal Administration of the Dopaminergic Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1990, Journal of neurochemistry.

[28]  M. Danhof,et al.  The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. , 2008, Journal of pharmacological and toxicological methods.

[29]  C. Tanner,et al.  Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.

[30]  Dorit Merhof,et al.  Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants , 2013, Archives of Toxicology.

[31]  M. Cookson,et al.  Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system , 2006, Neurobiology of Disease.

[32]  S. H. Bennekou,et al.  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition , 2017, Archives of Toxicology.

[33]  Marcel Leist,et al.  Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[34]  E. Richfield,et al.  A Fetal Risk Factor for Parkinson’s Disease , 2004, Developmental Neuroscience.

[35]  J. Okun,et al.  Three Classes of Inhibitors Share a Common Binding Domain in Mitochondrial Complex I (NADH:Ubiquinone Oxidoreductase)* , 1999, The Journal of Biological Chemistry.